Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Antivirals Market Value Growth And Long-Term Outlook
The antivirals market has experienced significant growth in recent years. Its value is anticipated to rise from $114.4 billion in 2025 to $122.08 billion in 2026, representing a compound annual growth rate (CAGR) of 6.7%. This historical expansion can be attributed to factors such as global viral outbreaks, the prevalence of HIV and hepatitis, government initiatives for antiviral stockpiling, the increased availability of generic medications, and the broadening scope of infectious disease programs.
The antivirals market is projected to experience substantial expansion over the coming years. This market is set to reach $163.33 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.5%. Factors driving this growth during the forecast period include the emergence of new viral threats, increased investment in antiviral research and development, greater integration of vaccination and treatment strategies, various global health initiatives, and a rising demand for rapid-response therapeutics. Key trends anticipated in this period encompass an escalating demand for broad-spectrum antivirals, a heightened emphasis on pandemic preparedness, the wider availability of generic antiviral drugs, increased application in managing chronic viral infections, and the innovation of antivirals with novel mechanisms.
Get A Free Sample Report With In-Depth Market Insights:
Antivirals Market Development Factors: What’s Supporting Demand?
A projected increase in influenza cases is expected to stimulate the expansion of the antiviral market moving forward. Influenza, commonly known as flu, is a highly transmissible viral respiratory infection caused by influenza viruses, affecting the nose, throat, and lungs. The rising frequency of influenza is largely due to colder temperatures and indoor crowding, conditions that prolong the virus’s survival and facilitate its person-to-person spread in close proximity. Antivirals are utilized for treating influenza and function by hindering the replication and propagation of influenza viruses within the body. For instance, in November 2024, as reported by the Centers for Disease Control and Prevention, a US-based national public health agency, the 2023 to 2024 influenza season was estimated to have resulted in 40 million illnesses, 18 million medical visits, 470,000 hospitalizations, and 28,000 deaths. Consequently, the escalating incidence of influenza is propelling the growth of the antiviral market.
Antivirals Market Segment Trends And Revenue Contributors
The antivirals market covered in this report is segmented –
1) By Type: Branded, Generic
2) By Drug Class: DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Other Drug classes
3) By Application: HIV, Hepatitis, Herpes, Influenza, Other Applications
Subsegments:
1) By Branded: Antivirals For HIV Or AIDS, Antivirals For Hepatitis, Antivirals For Influenza, Antivirals For Herpes Simplex Virus (HSV)
2) By Generic: Generic HIV Or AIDS Antivirals, Generic Hepatitis Antivirals, Generic Influenza Antivirals, Generic Herpes Simplex Virus (HSV) Antivirals
Antivirals Market Transformation Trends: What Innovations Are Driving Change?
Major companies in the antiviral market are prioritizing the development of innovative treatments, such as oral antiviral medications, to enhance patient adherence, improve accessibility, reduce healthcare expenses, and offer more convenient and effective options for managing viral infections. Oral antiviral treatment refers to medicines taken by mouth to combat viral infections. These treatments function by inhibiting viruses from multiplying or spreading within the body, which helps to lessen the severity and duration of the infection. For instance, in May 2023, Pfizer, a US-based pharmaceutical company, announced that Paxlovid received approval from the Food and Drug Administration, a US-based government agency, making it the first oral antiviral treatment for COVID-19 in adults. This approval is particularly significant as it offers a new therapeutic alternative for managing COVID-19, especially as the pandemic moves towards an endemic phase. Paxlovid is specifically indicated for adults with mild-to-moderate COVID-19 who are at high risk of progressing to severe disease, including hospitalization or death.
Leading companies in the antiviral market are focused on creating advanced therapeutic solutions, including various antiviral treatments, to improve patient outcomes and decrease viral transmission. Antiviral treatments are crucial for controlling viral infections and preventing complications in affected patients. For example, in August 2024, Red Queen’s Technology, a US-based pharmaceutical company, launched versatile antivirals. Apple Tree Partners has invested $55 million in Red Queen Therapeutics, a biotech firm specializing in developing broad-spectrum antiviral treatments. The company targets infectious pathogens such as COVID-19 and influenza, having already advanced a COVID antiviral through Phase 1 testing and secured U.S. government funding for a pan-influenza drug. Co-founded by Harvard professor Loren Walensky, Red Queen utilizes stapled lipopeptides to inhibit viral fusion and block viral entry into cells.
Antivirals Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the antivirals market are AbbVie Inc., Bristol-Myers-Squibb Co., Chemical Industrial & Pharmaceutical Laboratories Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Ltd., Merck & Co. Inc., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Abbott Laboratories, Schering-Plough Corporation, Pfizer Inc., Sanofi-Synthélabo Ltd., Inovio Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., AVI Biopharma International Ltd., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Biogen Inc., Genentech USA Inc., Vertex Pharmaceuticals Inc.
View The Full Antivirals Market Report:
Antivirals Market Regional Analysis And Leading Geography
North America was the largest region in the anti-viral drug therapy market in 2025. The Middle East is expected to be the fastest-growing region in the antivirals market during the forecast period. The regions covered in the antivirals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model